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Abstract
Background: To determine if recommended treatment targets, as specified in clinical practice guidelines for the
management of cardiovascular disease, reduces the risk of renal complications in high risk patient populations.
Methods: This was a cohort study. Participants in Utrecht, The Netherlands either at risk of, or had cardiovascular
disease were recruited. Cardiovascular treatment targets were achievement of control in systolic and diastolic
blood pressure, total and low-density cholesterol, and treatment of albuminuria. Outcome measures were time to
development of end stage renal failure or symptomatic renal atherosclerotic disease requiring intervention.
Results: The cohort consisted of 7,208 participants; 1,759 diabetics and 4,859 with clinically manifest vascular
disease. The median age was 57 years and 67% were male. Overall, 29% of the cohort achieved the treatment
target for systolic blood pressure, 39% for diastolic blood pressure, 28% for total cholesterol, 31% for LDL
cholesterol and 78% for albuminuria. The incidence rate for end stage renal failure and renal atherosclerotic disease
reduced linearly with each additional treatment target achieved (p value less than 0.001). Achievement of any two
treatment targets reduced the risk of renal complications, hazard ratio 0.46 (95% CI 0.26-0.82). For patients with
clinically manifest vascular disease and diabetes, the hazard ratios were 0.56 (95% CI 0.28 - 1.12) and 0.28 (95%CI
0.10 - 0.79) respectively.
Conclusion: Clinical guidelines for cardiovascular disease management do reduce risk of renal complications in
high risk patients. Benefits are seen with attainment of any two treatment targets.
Background
Current clinical practice guidelines for the management
of patients with diabetes, hypertension and other athero-
sclerotic risk factors are geared to the prevention of car-
diovascular disease and its complications [1-3]. However,
c a r d i o v a s c u l a rd i s e a s e sa r en o tt h eo n l yc o m p l i c a t i o n s
that can arise. Renal complications such as renal athero-
sclerotic disease [4] and end stage renal failure (ESRF)
are of equal importance [5-9] though not as common.
There are few studies looking at the effects of com-
bined cardiovascular treatment targets on renal compli-
cations; most are aimed at cardiovascular complications
for which the targets were derived for. The risk of renal
complications is low [10] despite the high prevalence of
diabetes and hypertension [11,12], and is usually con-
fined to those with a genetic predisposition [13,14]. In
clinical practice, these complications arise after a long
duration of disease and/or treatment [15]. In the mean-
time, these patients undergo the same clinical manage-
ment as those who are not predisposed to renal
diseases. Studies of natural history of reno-atherosclero-
tic disease have shown that control of blood pressure do
not necessarily prevent the progression of renal disease
[16]. Therefore, it is relevant to determine whether the
current clinical guidelines which have treatment targets
geared for cardiovascular disease reduce the risk of
renal complications.
This study will evaluate if the current 2007 European
treatment guidelines for the prevention of cardiovascular
disease concomitantly reduces the risk of renal compli-
cations in patients at high risk of vascular diseases. We
assessed whether there is an inverse dose-response risk
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gets achieved or if there is an optimal number instead.
We also determined if there are differences in targets to
be achieved for two high risk patient groups; diabetics
and those with clinically manifest vascular disease.
Methods
Study design and population
The Second Manifestations of ARTerial disease
(SMART) study is a prospective cohort study that is
conducted in the University Medical Centre (UMC)
Utrecht. It commenced in September 1996 and is cur-
rently on-going. Patients aged 18 to 80 years with clini-
cally manifest atherosclerotic vascular disease, newly
referred to the UMC are invited to participate. Diseases
that qualify for enrolment are internal carotid artery ste-
nosis, transient ischemic attack, minor stroke, peripheral
arterial disease, diabetic foot, angina pectoris, myocardial
infarction, abdominal aortic aneurysm, and renal artery
stenosis. Those treated for cardiovascular risk factors,
including hyperlipidaemia, diabetes mellitus, hyperten-
sion and renal insufficiency are also recruited. Patients
with terminal cancer, dependent in their daily activities
or not fluent in Dutch are excluded. All cohort mem-
bers are followed up for a minimum of three years
using biannual questionnaires.
The study was approved by the UMC Utrecht Institu-
tional Review Board, which is approved by the Dutch
Central Committee for research involving human sub-
jects. The study was conducted in accordance with prin-
ciples of the Declaration of Helsinki. Written informed
consent was obtained from all participants. The ratio-
nale and design of the SMART study have been
described elsewhere [17].
The current study selected all patients without end
stage renal failure at baseline, recruited from September
1996 till February 2008. Every patient who was enrolled
in the SMART study had physical examinations at base-
line. Blood pressure was measured using a sphygmo-
manometer on both upper arms. The measurement was
repeated on the arm with the highest value. The maxi-
mal value was used in this study.
Hypertension was diagnosed based on a systolic blood
pressure of more or equal to 140 mm Hg and/or a dia-
stolic blood pressure of more or equal to 90 mm Hg or
being treated with two or more anti-hypertensive medi-
cations. Diabetes was determined based on self-report,
hyperglycaemia at baseline (> 7.0 mmol L
-1), glycated
haemoglobin (HbA1c) of more than 7% or being treated
with glucose lowering therapy.
Clinical measurements
The exposure of interest was number of cardiovascular
risk factor treatment targets achieved at baseline. Treat-
ment targets were defined according to the 2007 Eur-
opean guidelines [18] for high risk patients and were
limited to the management of risk factors that were
modifiable using drug therapy. Targets were systolic and
diastolic blood pressure, total cholesterol and low den-
sity lipoprotein (LDL) and albuminuria. For albuminuria
status, the target to achieve was no micro-albuminuria.
For those with albuminuria (micro-albuminuria or pro-
teinuria), the desired target was the appropriate choice
of therapy for albuminuria; treatment with either an
angiotensin-converting enzyme inhibitor (ACEI) or
angiontensin II receptor blocker (ARB). The choice of
renin-angiotensin system (RAS) inhibitor use as a treat-
ment goal is due to its effects on albuminuria, indepen-
dent of blood pressure lowering. RAS inhibitors either
improve albuminuria by reducing excretion (regression
or stabilization)[19-21] or by delaying the time to pro-
gression [22]. Diabetics had an additional target; HbA1c.
Patients had a maximum of five targets to achieve
whereas those with diabetes had six. Table 1 depicts the
treatment targets for this study. In the final analysis, the
treatment categories were condensed to five categories;
≤ 1: those who had none or only one target achieved, 2,
3, 4, ≥ 5 those who had five and/or all targets achieved.
Biochemical measurements
The biochemical assays measured in this study has been
described in detail previously [17]. In summary, a
venous blood sample was taken to determine lipid, glu-
cose and creatinine levels. Plasma total cholesterol,
Table 1 Cardiovascular risk factor treatment targets
Treatment targets
Risk factor All patients without Diabetes Diabetes mellitus
Systolic blood pressure (mm Hg) < 130 < 130
Diastolic blood pressure (mm Hg) < 80 < 80
Total cholesterol (mmol L
-1) < 4.5 < 4.5
Low density lipoprotein (mmol L
-1) < 2.5 < 2.5
HbA1c (%) - < 6.5
Microalbuminuria and proteinuria Treatment with ACEI/ARB or No proteinuria Treatment with ACEI/ARB (Any albuminuric state)
ACEI: angiotensin-converting enzyme inhibitor
ARB: angiontensin II receptor blocker
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using a commercial enzymatic dry chemistry kit (John-
son and Johnson). HDL-cholesterol in plasma was deter-
mined using a commercial enzymatic kit (Boehringer-
Mannheim) after precipitation of LDL and very low den-
sity lipoprotein (VLDL) with sodium phosphotungstate
magnesium chloride. LDL-cholesterol was calculated
using the Friedewald formula.
A urine sample was collected to measure micro-
albuminuria and creatinine excretion. Creatinine was
measured using a commercial enzymatic dry chemistry
kit (Johnson and Johnson) and micro-albuminuria was
determined with immunoturbidimetric assays (Boehringer-
Mannheim).
Primary outcome
Renal outcomes were defined as a composite endpoint
consisting of end stage renal failure requiring renal repla-
cement therapy and reno-atherosclerotic disease requiring
intervention; either arterial stenting or bypass grafting.
Time to any renal endpoint was the outcome of interest.
During the follow up period, outcomes were deter-
mined through questionnaires biannually. Participants
provided information on hospitalization and clinic visits.
Original source documents were reviewed if a hospitali-
zation or clinic visit was reported. All hospital discharge
letters and results of related laboratory and radiological
examinations were collected. Each event was classified
according to a standard operating procedure. All end-
points were adjudicated by three members of the
SMART Endpoint Committee, comprising of physicians
from different departments.
The participants were followed up till death or refusal
to participate.
Statistical analysis
Analysis was performed using SPSS version 17.0 for
Windows (SPSS Inc., Chicago, IL, USA). Baseline data
displayed was calculated using a general linear model
for continuous variables adjusted for age and sex. P
values for trends across the five treatment target groups
were estimated using Mantel Haenszel’s c2. Ordinal
data was tested using ordinal tests (Kendall’s tau).
Confounders were selected a priori for testing based
on literature. Variables selected were age, sex, waist cir-
cumference, history of coronary artery disease, cerebro-
vascular disease, peripheral arterial disease and renal
disease, smoking status (never, former, current), alcohol
consumption (never, ever, recently stopped, current),
haemoglobin levels, albuminuria status (no, micro-albu-
minuria, overt proteinuria) and estimated glomerular fil-
tration rate (eGFR) using the Modification of Diet in
Renal Disease (MDRD) formula. These were then deter-
mined to be included in the final model if there was a
change in the hazard ratio (HR) estimate of more than
10 percent when compared to the crude estimate [23].
Medication was seen as not confounders in this study
because the type and number of drugs used were pri-
marily to achieve treatment targets. Medications which
had independent action on renal function such as
ACEIs and ARBs were already included as a treatment
target for albuminuria.
A multivariate Cox proportional hazards model was
used to determine the association between the number
of treatment targets achieved and the risk of renal com-
plications. Hazard ratios and the 95% confidence inter-
vals were calculated for each number of treatment
targets achieved, with the category of one or less targets
achieved as reference. The likelihood ratio test was used
to determine the significance of the variables included
in the model. A p value of less than 0.05 (two tailed)
was considered to be statistically significant. Analysis
was performed with two adjustments; 1) adjustment for
statistically significant confounders 2) adjustment for
statistically significant confounders, age and sex. For
participants from the whole cohort, the significant con-
founders were hypertension, albuminuria, eGFR and
haemoglobin levels. For those with clinically manifest
vascular disease, the confounders were hypertension,
albuminuria and eGFR levels. Only eGFR and haemoglo-
bin were significant confounders for participants with
diabetes. The Wald test was used to determine if treat-
ment targets were significant as a linear variable. A p
value of less than 0.05 was considered to be statistically
significant.
The assessment of hazard ratios for individual treat-
ment targets was done at a quantitative level. There was
a statistically significant correlation between systolic and
diastolic blood pressure. Pearson’s correlation coefficient
r was 0.68 with a p value of less than 0.001 (two tailed).
There was stronger correlation between total cholesterol
and LDL levels, Spearman’s correlation coefficient rho
0.88 was statistically significant at a p value of less than
0.001 (two tailed). When testing the hazard ratios at the
risk factor level, due to the high correlation between
these variables, only one from each set of these factors
was chosen; systolic blood pressure and LDL. Both sys-
tolic blood pressure and LDL cholesterol levels are the
more important treatment targets for the prevention of
cardiovascular disease [24,25]. Cox proportional hazards
assumptions were tested visually using hazard and Log
Minus Log (LML) plots.
Incidence rates were calculated using the number of
events, divided by the total person time in years. The
time period is calculated from baseline till event, death
or loss to follow up.
Missing data was reviewed to determine if it was
Missing At Random. Those missing at less than one
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w h e r ea p p l i c a b l e .S i n g l ei m p u t a t i o nu s i n gal i n e a r
regression with an error term was done for other vari-
ables. This was done for four variables; albuminuria
(6.2% missing), LDL (6.9% missing), waist circumference
(17.6% missing) and HbA1c for diabetics (38.1%
missing).
Results
Between September 1996 and February 2008, 7,292 par-
ticipants were enrolled in the SMART study cohort. Of
these, the 84 participants who had end stage renal fail-
ure at baseline were excluded from this study. At the
end of the study period, 670 had died and 253 were lost
to follow up. The median duration for follow up was
4.21 years (IQR 2.08 - 7.11).
Characteristics of the participants
The cohort consisted of 7,208 participants. There were
4,859 (67.4%) with clinically manifest vascular disease
and 1,759 (24.4%) diabetics, both conditions not
mutually exclusive. Other participants had risk factors
without clinical evidence of atherosclerotic disease. The
median age was 57 years (IQR 48 - 66) and 67.2% were
male. Overall, 29.1% of the cohort fulfilled the treatment
target for systolic blood pressure, 38.5% for diastolic
blood pressure, 28.2% for total cholesterol, 30.7% for
LDL cholesterol and 77.9% for albuminuria. About 47%
of those prescribed beta blockers had ischaemic heart
disease. Only 12% of those prescribed beta blockers
were due to hypertension.
Table 2 summarizes the baseline characteristics of the
whole cohort. Those who achieved all five targets were
more likely to be male, had more often a previous his-
tory of coronary artery disease, consumed alcohol, had
lower levels of triglycerides and micro-albuminuria or
proteinuria was less common.
Among those with clinically manifest vascular disease,
29.2% achieved the systolic blood pressure treatment
target, 43.3% the diastolic blood pressure target, 33.7%
the total cholesterol target, 34.8% the LDL target and
78.9% the appropriate treatment target for albuminuria.
Among the diabetic participants, 24.6% achieved the sys-
tolic blood pressure treatment target, 38.1% the diastolic
blood pressure target, 33.9% the total cholesterol target,
38.2% the LDL target, 41% achieved appropriate treat-
ment of albuminuria and 26.9% achieved the HbA1c tar-
get. The diabetics had poorer control of blood pressure
and less use of RAS inhibitors for the treatment of albu-
minuria than the general cohort.
Primary objective
At the end of the follow up period, there were 81 renal
endpoints (Table 2). The unadjusted incidence rate for
renal endpoints was 2.41 per 1,000 person-years. There
were 57 renal endpoints for end stage renal failure with
an incidence rate of 1.7 per 1,000 person-years. For
renal atherosclerotic disease, there were 24 events with
an incidence rate of 0.71 per 1,000 person-years. There
was a statistically significant linear trend (p value less
than 0.001) for incidence rate reduction with increasing
target achievement.
The attainment of two or more treatment targets
at baseline decreased the unadjusted risk of renal end-
point development for all groups except the diabetics
(Table 3). The decreased unadjusted risks were statisti-
cally significant for trends. After adjustment for con-
founding variables such as age, sex, eGFR, albuminuria
status, haemoglobin and hypertension, the hazard ratios
for renal endpoints remained statistically significant for
trends in the overall cohort and for those with clinically
manifest vascular disease.
Secondary objective
When individual cardiovascular risk factors were com-
pared, there was an increased risk of developing any
renal endpoint for each increase in unit of systolic blood
pressure, LDL and HbA1c levels. The hazard ratios for
all risk factors were similar for all subgroups of patients,
except for the hazard ratio of HbA1c among diabetics.
Each unit increase in HbA1c levels suggests a higher
rate of increase in the hazard ratio for renal complica-
tions in diabetics, than in the general cohort or in those
with clinically manifest vascular disease.
Discussion
In this cohort study, we studied whether the attainment
of treatment targets established for the prevention of
cardiovascular disease would concomitantly reduce the
rate of renal complications. Based on the current 2007
European clinical practice guidelines, we observed that
the achievement of any two or more treatment targets
at baseline do reduce the rates of renal complications,
for patients at high risk of atherosclerotic disease and
for those with clinically manifest vascular disease.
Although this observation was not statistically significant
for diabetics, it may be clinically beneficial. A previous
study of diabetics showed a decline in renal complica-
tions if three or more treatment targets were achieved
[26]. With increasing treatment targets achieved, a lower
haemoglobin concentration level was seen. However, it
was not associated with poorer outcomes. This may be
a result of more liberal use of RAS inhibitors, which
decreases erythropoiesis [27]. There was no optimal
number of cardiovascular risk factor treatment targets
to achieve. The risk of renal complications decreased
linearly as more targets were attained; consistent with
the notion that no J-curve exists for renal outcomes.
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treatment targets achieved at baseline
Treatment Targets Achieved
Characteristics ≤ 12 3 4≥ 5 p value for trends
n 2813 1652 1785 593 365
Age (years)
a 57 (49,66) 57 (48,66) 56 (47,64) 58 (50,66) 55 (46,64)
Male sex 65.6 (1845) 65.9 (1088) 67.3 (1202) 73.9 (438) 75.1 (274) 0.001
Smoking
Current 32.1 (902) 33.7 (556) 30.3 (541) 29.3 (174) 30.7 (112)
Former 41.7 (1174) 42.3 (698) 45.2 (806) 43.8 (260) 46.3 (169)
Never 26.2 (737) 24.1 (398) 24.5 (438) 26.8 (159) 23 (84)
Packyears 18 ± 0.36 19 ± 0.46 18 ± 0.45 18 ± 0.77 17 ± 0.99
Alcohol consumption 0.001
Never 20.8 (584) 21.7 (358) 19.9 (355) 18.2 (108) 18.1 (66)
Ever 9.7 (273) 9 (148) 9.8 (175) 10.8 (64) 12.9 (47)
Recently stopped 29.5 (831) 28.5 (470) 23.1 (412) 16.5 (98) 14.2 (52)
Current 40 (1125) 40.9 (676) 47.2 (843) 54.5 (323) 54.8 (200)
History of:
Coronary artery disease 26.5 (745) 36.7 (607) 49 (875) 63.4 (376) 71 (259) 0.001
Cerebrovascular disease 19.9 (561) 20.8 (343) 17.9 (319) 18.4 (109) 15.6 (57) 0.027
Peripheral arterial disease 16.8 (472) 17.1 (283) 13 (232) 8.4 (50) 7.9 (29) 0.001
Previous kidney disease 2.6 (74) 2.7 (44) 2.7 (48) 4.9 (29) 3.6 (13)
Any of the above 56.7 (1595) 64.5 (1065) 71.8 (1281) 82.1 (487) 87.1 (318) 0.001
BMI (kg m
-2) 27 ± 0.08 27 ± 0.11 27 ± 0.10 27 ± 0.18 26 ± 0.23 0.001
Waist circumference (cm) 95 ± 0.22 94 ± 0.29 93 ± 0.28 94 ± 0.49 92 ± 0.62 0.001
Systolic BP (mm Hg) 154 ± 0.34 141 ± 0.44 135 ± 0.43 130 ± 0.74 119 ± 0.95 0.001
Diastolic BP (mm Hg) 91 ± 0.20 82 ± 0.26 79 ± 0.25 75 ± 0.44 71 ± 0.56 0.001
S. Glucose (mmol L
-1) 6.5 ± 0.04 6.6 ± 0.06 6.1 ± 0.05 6.6 ± 0.09 5.9 ± 0.12 0.001
HbA1c (%) 6.1 ± 0.02 6.2 ± 0.03 5.9 ± 0.03 6.1 ± 0.05 5.8 ± 0.06 0.001
Total cholesterol (mmol L
-1) 5.95 ± 0.02 5.45 ± 0.03 4.87 ± 0.03 4.02 ± 0.05 3.76 ± 0.06 0.001
HDL cholesterol (mmol L
-1) 1.28 ± 0.01 1.25 ± 0.01 1.25 ± 0.01 1.24 ± 0.02 1.20 ± 0.02 0.001
LDL cholesterol (mmol L
-1) 3.75 ± 0.02 3.23 ± 0.03 2.84 ± 0.03 2.04 ± 0.05 1.95 ± 0.06 0.001
Triglycerides (mmol L
-1) 2.05 ± 0.04 2.16 ± 0.05 1.74 ± 0.05 1.65 ± 0.09 1.38 ± 0.11 0.001
Creatinine (μmol L
-1) 92.3 ± 0.87 93.9 ± 1.13 92.1 ± 1.09 91.6 ± 1.88 93.1 ± 2.40
Microalbuminuria 21.9 (616) 16.5 (272) 9.7 (174) 13.8 (82) 7.9 (29) 0.001
Proteinuria 3.6 (102) 2.8 (46) 1.4 (25) 1.9 (11) 0.8 (3)
eGFR (mL min-1 1.73 m-2) 78.1 ± 0.33 77.6 ± 0.43 77.9 ± 0.41 78.7 ± 0.71 78.1 ± 0.91
Haemoglobin (mmol L
-1) 9.0 ± 0.01 8.8 ± 0.02 8.8 ± 0.02 8.7 ± 0.03 8.6 ± 0.04 0.001
Patients with Hypertension 84.9 (2387) 62.3 (1029) 54.2 (968) 55.3 (328) 41.4 (151) 0.001
Duration of hypertension (years) 6.0 ± 0.19 5.1 ± 0.24 4.8 ± 0.23 5.5 ± 0.40 4.5 ± 0.51 0.001
Use of BP lowering drugs 62.2 (1749) 61.8 (1021) 64.8 (1157) 75.9 (450) 79.2 (289) 0.001
Type of BP lowering drugs
b-blockers 29.6 (834) 36 (594) 42.7 (762) 50.9 (302) 60.8 (222) 0.001
Diuretics 18.3 (516) 16.6 (274) 16.6 (296) 22.8 (135) 16.4 (60)
ACE inhibitors 20.5 (576) 22.8 (377) 26.8 (478) 33.1 (196) 32.3 (118) 0.001
ARBs 7.2 (203) 6.6 (109) 7.1 (126) 11.5 (68) 8.5 (31)
Calcium channel blockers 15.2 (428) 15.7 (260) 16.1 (288) 20.2 (120) 18.1 (66) 0.015
Number of BP lowering drugs 0.001
1 27.3 (768) 26.8 (443) 26.3 (470) 28.8 (171) 37.5 (137)
2 18.3 (515) 18.9 (313) 22.7 (406) 27 (160) 24.7 (90)
3 7.6 (214) 9.1 (151) 10.2 (182) 13.8 (82) 14.8 (54)
≥ 4 1.8 (51) 2.1 (33) 2.1 (36) 3.9 (23) 1.4 (5)
Use of Lipid lowering drugs 32.7 (920) 43.6 (721) 57 (1017) 72.7 (431) 77.3 (282) 0.001
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ment targets achieved at baseline (Continued)
Patients with Diabetes 24.4 (686) 28.8 (475) 17.8 (318) 34.7 (206) 20.3 (74)
Duration of diabetes (years) 1.4 ± 0.09 1.8 ± 0.12 1.3 ± 0.12 2.2 ± 0.21 1.3 ± 0.26
Use of oral anticoagulants 43.1 (1211) 51.7 (854) 60 (1071) 74.5 (442) 77.3 (282) 0.001
Endpoints
End stage renal failure 35 14 5 2 1
Reno-atherosclerotic disease 1 5 3510
Number of total events 50 17 10 3 1
Total person years 14209 8195 7766 2205 1218
Incidence rate per 1000 population 3.52 2.07 1.29 1.36 0.82 < 0.001
Continuous variables are expressed as age and sex adjusted means with SE; categorical variables are expressed as percentages with numbers in parenthesis;
amedian with interquartile range
Table 3 Hazard ratios of renal endpoints by number of cardiovascular risk factor treatment targets achieved
All Clinically Manifest Vascular Disease Diabetes
HR (95% CI) p for trends HR 95% CI p for trends HR 95% CI p for trends
n 7208 4859 1759
number of events 81 52 28
Renal endpoint
Model 1 (crude)
Targets achieved
≤ 1 1.00 0.001 1.00 0.0001 1.00 0.704
2 0.59 (0.34, 1.02) 0.51 (0.26, 1.00) 0.69 (0.27, 1.81)
3 0.36 (0.18, 0.71) 0.23 (0.09, 0.59) 1.09 (0.39, 3.05)
4 0.37 (0.12, 1.19) 0.29 (0.07, 1.22) 0.99 (0.29, 3.47)
≥ 5 0.22 (0.03, 1.59) 0 0 0 0
Model 2 adjusted a b c
Targets achieved
≤ 1 1.00 0.018 1.00 0.021 1.00 0.174
2 0.49 (0.28, 0.86) 0.58 (0.29, 1.14) 0.37 (0.13, 1.00)
3 0.54 (0.27, 1.09) 0.38 (0.15, 0.99) 0.62 (0.22, 1.80)
4 0.46 (0.14, 1.51) 0.64 (0.15, 2.69) 0.54 (0.15, 1.99)
≥ 5 0.42 (0.06, 3.11) 0 0 0 0
Model 3 adjusted
d
Targets achieved
≤ 1 1.00 0.013 1.00 0.018 1.00 0.107
2 0.46 (0.26, 0.82) 0.56 (0.28, 1.12) 0.28 (0.10, 0.79)
3 0.51 (0.26, 1.03) 0.36 (0.14, 0.95) 0.39 (0.12, 1.26)
4 0.49 (0.15, 1.60) 0.63 (0.15, 2.67) 0.56 (0.16, 2.01)
≥ 5 0.37 (0.05, 2.76) 0 0 0 0
Risk factors
e
SBP (per mmHg) 1.02 (1.01, 1.03) 1.02 (1.01, 1.03) 1.03 (1.01, 1.05)
LDL (per mmol/L) 1.26 (1.04, 1.53) 1.31 (1.02, 1.68) 1.21 (0.83, 1.75)
Treatment for albuminuria 0.90 (0.57, 1.43) 0.97 (0.55, 1.70) 0.58 (0.24, 1.39)
HbA1c (per %) 1.18 (1.01, 1.38) 1.20 (0.96, 1.49) 1.44 (1.12, 1.84)
aadjusted for hypertension, albuminuria, eGFR and haemoglobin levels
badjusted for hypertension, albuminuria and eGFR levels
cadjusted for eGFR and haemoglobin levels
dadjusted for Model 2 + age and sex
eadjusted for age, sex, hypertension, albuminuria, eGFR and haemoglobin levels
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clinically manifest vascular disease population cohorts.
Primarily, the decreased hazard ratios for renal out-
comes in diabetics were only observed after the model
was adjusted for renal confounders such as eGFR and
haemoglobin levels. This may be because once chronic
renal disease has set in, achievement of treatment tar-
gets alone is insufficient to reduce or retard the rate of
complications in diabetics. This was not the case for
those with manifest vascular disease, where there was a
consistent reduced risk of renal complications even with
non-adjustment for renal confounders. The second dis-
tinct difference is, there does not appear to be a gradi-
ent decreased hazard ratio for diabetics as the number
of treatment targets achieved increased. A previous
study of treatment targets and cardiovascular outcomes
in diabetics showed a graded response [28].
The low percentage of participants achieving treat-
ment targets is consistent with other countries. In a
Swedish study, only 17% of their hypertensive popula-
tion had achieved a systolic blood pressure target of less
than 140 mmHg and 64% achieved the diastolic blood
pressure target of less than 90 mmHg [29]. In the Losar-
tan Intervention For Endpoint reduction in hypertension
(LIFE) study, which was a multi country randomized
control trial, only 16.3% had achieved the total choles-
terol target of less than 5.0 mmol/l at baseline [30]. In
the United Kingdom, only 19.7% and 26.9% achieved
blood pressure and cholesterol targets respectively [31].
More patients achieving the target for diastolic blood
pressure than for systolic blood pressure is also consis-
tent with other studies [29]. This is probably reflective
of older, stiffer arteries which is expected in high risk
patients, and not because therapies used were more
effective in lowering diastolic blood pressure.
Looking at the individual cardiovascular risk factor
levels, the findings amongst the study population is con-
sistent with current literature. With increasing systolic
blood pressure [32], LDL and HbA1c, the risk for renal
complications increases statistically significantly. Consid-
ering the similar risks for renal complications in all
cohort groups with increasing systolic blood pressure
and LDL levels, the treatment of HbA1c levels is crucial
in diabetics. The non-significant decreased hazard ratio
seen in all patient groups for the treatment of albumi-
nuria may be due to two reasons; suboptimal dosing or
discontinuation of medication due to non-response to
blood pressure lowering with ACEI or ARB use. Inade-
quate dosing of ACEI or ARB’s causes less anti-albumi-
nuric activity thus there is suboptimal reduction in
albuminuria. Aside from this, non-response to blood
pressure reduction does not mitigate the effects of anti-
albuminuric activity; therefore discontinuation of these
drugs increases the risk of renal endpoints [33].
This study has a few limitations. The number of treat-
ment targets achieved was determined only at baseline.
Over the entire duration of follow up, patients may fluc-
tuate between different categories of targets achieved,
depending on clinical management received.
The duration of follow up may be insufficient for
ESRF development in many patients. In the UKPDS
study, development of renal endpoints occurred in only
0.8% after a median of 10 years [34]. Aside from this,
the number of events that occurred was small, 81 in
total and in diabetics 28. This may explain the lack of
power in proving statistical significance, except for the
tests for trends. A longer follow up duration would pro-
vide more accurate estimates and therefore stronger evi-
dence. Nevertheless, this study had a total sample size
of 7,208 participants with a sum of 33, 593 person-years
of follow up. This is sizable.
Another key strength of this study is the use of hard
endpoints; end stage renal failure and symptomatic renal
vascular disease requiring intervention. We did not use
surrogate endpoints such as rate of GFR decline because
in diabetics and in other patient populations, the calcu-
lated GFR using the MDRD formula underestimates the
rate of renal function loss [35-37]. It also becomes inac-
curate as renal function improves; real GFR can fluctu-
ate between 35 to 90 mL min
-1 1.73 m
-2 for an eGFR of
60 mL min
-1 1.73 m
-2 [38]. Aside from this, stabilization
or regression of renal function decline has been known
to occur in patients treated with ACEI despite having
severe GFRs [39]. In this study, the maximum survival
time for an eGFR of less than 15 mL min
-1 1.73 m
-2
was 6.27 years.
These hard endpoints reflect different pathophysiolo-
gical mechanisms. End stage renal failure may be caused
by both micro and macrovascular changes whereas renal
vascular disease is caused by macrovascular changes.
Despite these differing pathophysiological mechanisms,
these findings are suggestive that the same treatment
targets reduce their risk of development.
Conclusion
This study shows that current clinical practice guideline
targets for the prevention of cardiovascular disease are
useful in concomitantly reducing the risk of renal com-
plications; in any patient population at high risk for vas-
cular diseases. If more patients can be adequately
treated to achieve the cardiovascular risk factor treat-
ment targets, there will be important reductions in renal
complications.
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